Safe use of CFTR modulators in pregnancy: A case study

Bayrak A. C., FADILOĞLU E., Kayikci U., YILAN B. S., KARA A., KARCIOĞLU O., ...Daha Fazla

TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, cilt.73, sa.2, ss.156-159, 2025 (ESCI, Scopus, TRDizin) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 73 Sayı: 2
  • Basım Tarihi: 2025
  • Doi Numarası: 10.5578/tt.202502923
  • Dergi Adı: TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Central & Eastern European Academic Source (CEEAS), EMBASE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.156-159
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Cystic fibrosis (CF) poses unique challenges during pregnancy. In this report, we aimed to present a 27-year-old CF patient with the G85E mutation who conceived during elexacaftor-tezacaftor-ivacaftor (ETI) treatment and continued ETI throughout pregnancy. Despite a temporary interruption of treatment during the first trimester, the patient experienced improved lung function, with no drug-related side effects. At 36 weeks, she suffered a mild exacerbation, which was successfully managed with antibiotics. A healthy infant with normal CF screening tests was delivered at 38+2 weeks of gestation. Our case adds to the limited evidence supporting the safety and benefits of CFTR gene modulators during pregnancy.